Recommended

Download this feature partnership: Continuous manufacturing: an evolving technology for drug substance manufacturing
New webinar: Defining the right digital strategy for oncology: What do you want to measure?
Join now: Pharmaceutical continuous manufacturing: what’s next for industry?
Register now for our upcoming webinar: Enhancing oral drug delivery: Exploring multiparticulate systems
Download our latest in-depth focus to read articles on single temperature incubation, endotoxin standards and aseptic connections in pharma manufacturing.
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
Register now: Simplifying complex dosage forms with advanced encapsulation
Join our webinar: Unmasking the unknown: how mass spectrometry delivers accurate identifications
reference

Patient adherence: the true costs

References for ‘Patient adherence: the true costs’, in European Pharmaceutical Review Issue 3 2020.

References

  1. DiMatteo MR. Social support and patient adherence to medical treatment: A meta-analysis. Health Psychol. 23, 2004, 207-218.
  2. Chesney MA. Factors affecting adherence to antiretroviral therapy. Infect. Dis., 30(S2) 2000 S171-176.
  3. Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Ther Clin Risk Manag., 1(3), 2005,189–199.
  4. Sutton SS, Magagnoli J, Hardin JW. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients With HIV Infection and AIDS Receiving Antiretroviral Therapy. Pharmacotherapy, 36(4), 2016a,385-401.
  5. Srivastava K, Arora A, Kataria A, Cappelleri JC, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 7, 2013, 419–434.
  6. Ming RT, Teo V, Yu HK, Raaj S, et al. Association between number of doses per day, number of medications and patient’s non-compliance, and frequency of readmissions in a multi-ethnic Asian population. Preventive Med. Rep., 1, 2014, 43-47.
  7. Elder DP, Kuentz M, Holm R. Antibiotic Resistance: The Need For a Global Strategy. Pharm. Sci., 105, 2016, 2278-2287.
  8. Hay M, Thomas DW, Craighead JL, Economides C, et al. Clinical development success rates for investigational drugs. Biotechnol., 32, 2014, 40-51.
  9. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, et al. Economic impact of medication nonadherence by disease groups: a systematic review. BMJ Open 2018;8:e016982. doi:10.1136/bmjopen-2017-016982. Accessed 05 June 2020.
  10. Currie CJ, Peyrot M, Morgan CL, Poole CD, et al. The Impact of Treatment Noncompliance on Mortality in People with Type 2 Diabetes. Diabetes Care, 35(6), 2012, 1279–1284.
  11. Satsoglou S, Tziomalos K. Fixed‐dose combinations: A valuable tool to improve adherence to antihypertensive treatment. Clin. Hypertens., 20, 2018, 908–909.
  12. Lancet editorial. Treatment adherence: Can fixed dose combinations help? P91, 3(2), Lancet Diabetes & Endrocrinology, 1-2. DOI:https://doi.org/10.1016/S2213-8587(15)70011-2.
  13. Sutton SS, Hardin JW, Bramley TJ, D’Souza AO, et al. Single- Versus Multiple-Tablet HIV Regimens: Adherence and Hospitalization Risks. J. Manag. Care, 22(4), 2016b,242-8.
  14. EMC website. Triumeq 50 mg/600 mg/300 mg film-coated tablets. https://www.medicines.org.uk/emc/product/3318. Accessed on 06 June 2020.
  15. Siew A. Tackling challenges in the development of fixed dose combinations. Tech., 38(4), 2014, 1-2.
  16. Kanasty R, Low S, Bhise N, Yang J, et al. A pharmaceutical answer to nonadherence: Once weekly oral memantine for Alzheimer’s disease. Contr. Release, 303, 2019, 34-41.
  17. Wright JC, Burgess DJ (Eds.) Long Acting Injections and Implants, CRS Press, 2012.pp.1-557.